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ABSTRACT
Objective Rapid diagnostic tests for malaria seem cost
effective in standard analyses, but these do not take
account of clinicians’ response to test results. This study
tested the impact of clinicians’ response to rapid
diagnostic test or microscopy results on the costs and
benefits of testing at different levels of malaria
transmission and in different age groups.
Design Cost-benefit analysis using a decision tree model
and clinical data on the effectiveness of diagnostic tests
for malaria, their costs, and clinicians’ response to test
results.
Setting Tanzania.
Methods Data were obtained from a clinical trial of 2425
patients carried out in three settings of varying
transmission.
Results At moderate and low levels of malaria
transmission, rapid diagnostic tests were more cost
beneficial than microscopy, and both more so than
presumptive treatment, but only where response was
consistent with test results. At the levels of prescription of
antimalarial drugs to patients with negative tests that
have been found in observational studies and trials,
neither testmethodis likely to be cost beneficial, incurring
costs 10-250% higher, depending on transmission rate,
than would have been the case with fully consistent
responses to all test results. Microscopy becomes more
cost beneficial than rapid diagnostic tests when its
sensitivity under operational conditions approaches that
of rapid diagnostic tests.
Conclusions Improving diagnostic methods, including
rapid diagnostic tests, can reduce costs and enhance the
benefits of effective antimalarial drugs, but only if the
consistency of response to test results is also improved.
Investing inmethods to improve rational response to tests
is essential. Economic evaluations of diagnostic tests
should take into account whether clinicians’ response is
consistent with test results.
INTRODUCTION
Various diagnostic tests are being made available for
some of the major diseases in sub-Saharan Africa,
including HIV, sexually transmitted infections, and
malaria. Although these tests could improve the
targeting of drugs to those patients most in need, their
use could consume scarce funding with little effect if
clinicians’ response to test results is not taken into
account. Most economic evaluations assume that
clinicians will prescribe an antimicrobial agent to a
patientwithpositive test results andnot to apatientwith
negative results.
Improved targeting of antimalarial drugs in Africa is
a priority as new artemisinin combination therapies,
which cost much more than previous and now
generally ineffective antimalarials, come into use.
The widespread practice of treating any non-specific
febrile illness as malaria threatens the sustainability of
artemisinin combination therapy; in many settings
most antimalarial drugs are prescribed for patientswho
have no malaria parasites.1-3 Other potentially serious
causes of illness are ignored because of the assumption
that the cause of fever is malaria. Overprescription of
antimalarials has a great impact on the cost effective-
ness of artemisinin combination therapies.4 If artemi-
sinin combination therapies are to be afforded by the
poorest people, they will need to be subsidised, and
subsidies are also threatened by overprescription on
the current scale.
Reflecting these concerns, malaria treatment guide-
lines now recommend that treatment for non-severe
malaria should, at least for older children and non-
pregnant adults, be restricted to people with positive
results on a parasitological test for malaria. In many
settings this is difficult to achieve with blood slide
testing,which is of variable accuracyandavailable only
in larger health facilities, where a minority of patients
seek care. Recent improvements in rapid immuno-
chromatographic diagnostic tests for malaria poten-
tially solvemany of these problems; also, the testscost
less than most courses of artemisinin combination
treatment.5 6 Studies that have explored the economic
consequences of using rapid diagnostic tests alongside
artemisinin combination therapies have shown these
tests are cost effective, but these studies assume that
prescribers respond to negative test results by not
prescribing an artemisinin combination therapy.57-9
The assumption in these models—that prescribers
will respond in a way that is fully consistent with test
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results—is unsafe. In Zambia, where rapid diagnostic
tests are used routinely in settings wheremicroscopy is
not available, antimalarials continued to be prescribed
to over a third of patientswhohadnegative test results.2
In Tanzania, a recent randomised trial of rapid
diagnostic tests compared with blood slide testing
found that in low transmission areas, over 90% of all
antimalarials prescribed were given to patients with a
negative test result, irrespective of the test method
used.3 These levels of overprescribing extend also to
patients with severe illness.10
Using data from a trial of clinicians’ behaviour, this
paper examines the relation between the level of
response consistent with results of parasitological tests
and the total costs resulting from the use of rapid
diagnostic tests and microscopy. Both diagnostic
methods are evaluated, as microscopy is likely to
continue to have an important role in themanagement
of febrile patients. We consider the costs of diagnosis
and treatment and the cost of life years lost through
incorrect diagnosis and inappropriate treatment.
METHODS
We obtained data from a randomised controlled trial
carried out in three hospitals in northeast Tanzania,
which compared clinicians’ response to microscopy
results against those for rapid diagnostic tests.3 The
relevant data for this analysis are prevalence of
parasitaemia among febrile patients, clinicians’
response to test results, the accuracy (sensitivity and
specificity) of the tests, and the cost of diagnosis and
treatment.
Prevalence is defined as the proportion of febrile
patients presenting with parasitaemia, and varies with
the rates of transmission of malaria.11 Prevalence of
under 10% is classified as likely when transmission is
low, 10-50% when moderate, and above 50% in high
transmission settings. Consistent response rate is
defined as the percentage of negative test results for
which clinicians do not prescribe antimalarials: at a
consistent response rate of 100%, no patient with a
negative test receives an antimalarial; at consistent
response rate of 0%, all patients with a negative test
receive an antimalarial. We did not examine incon-
sistent response to positive test results as this was a rare
occurrence (<1%). Prescribing antibiotics to patients
with negative test results was set at just over 50%,
independently of provision of an antimalarial, as
documented in the trial. (Whether or not patients
with negative test results received an antimalarial, just
over half had received an antibiotic in the trial.3) We
derived the estimates for the accuracy of the rapid
diagnostic tests and microscopy by combining data
from all three sites in the trial.
We calculated the costs for the management of a
simulated population of 1000 patients, including costs
of microscopy or rapid diagnostic tests, antimalarials,
antibiotics, care for patients with severe illness, and a
cost representing the value of life years lost owing to
incorrect diagnosis. The analysis primarily compares
the varying costs of microscopy and rapid diagnostic
Table 1 | Variables in assessing response tomalarial testing
Measure Estimate used Source Comment
Costs*
Rapid diagnostic test $0.80 Primary data5
Microscopy $0.28 Lubell et al5 Low cost is partly result of short
reading time
Artemisinin combination therapy $2.40 adult dose WHO24 Quantities adjusted for younger age
groups
Antibiotics $0.30 Primary data5 Test negatives adhered to assumed
to receive drug of this cost
False negative result Varies by age, prevalence with
respect to probability of untreated
malaria becoming severe, and case
fatality rates (see below); value of
year of life lost=$150
WHO24 Value of year of life lost based on
WHO benchmark for “attractive”
interventions
False positive result Determined by proportion of non-
malarial febrile illnesses that are
bacterial, the probability they
become severe, and case fatality
rates (see below); combined with
value for years of life lost
Accuracies
Rapid diagnostic test:
Sensitivity 93% Primary data3
Specificity 96% Primary data3
Microscopy:
Sensitivity 73% Primary data3
Specificity 93% Primary data3
*Costs were collected in Tanzanian shillings of 2005 and converted to US dollars ($1=1167 Tzs for 2005)
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tests with respect to action consistent with their results,
and also the cost of presumptively treating the
population, to indicate the circumstances in which
use of a test becomes inefficient.
The analysis uses a cost-benefit framework, taking a
societal perspective accounting for both provider costs
and the monetary value of years of life lost owing to
incorrect diagnosis and inappropriate treatment. This
framework allows for a more coherent analysis in
directly observing the impact of inconsistent response
with test results on total costs, without the need for cost
effectiveness ratios.
We chose a decision tree as the best model to
synthesise the data, represent alternative options, and
indicate the most efficient outcomes (fig 1). A number
of variables were made to interact—for instance, the
probability of developing severe malaria responded to
prevalence and age, as did treatment costs for
artemisinin combination therapies. In addition to the
influenceof ageonprobabilityof transmission andcase
fatality rates, the responsiveness of the model to
patients’ age was important for policy considerations,
since in some settings presumptive treatment is
recommended for younger patients.
Patients for whom the test provided an incorrect
result that the clinician acted on were classified as false
positives or false negatives. Their costs were estimated
with theuse of a simple flowchart as shown in the lower
panel of figure 1, following the model used by
Goodman et al and Coleman et al. 12 13 The probability
of an episode of malaria being self limiting was
determined according to the patient’s age and the
transmission rate, with varying case fatality rates
according to whether the patients were admitted as
inpatients (tables 1 and 2).
On the death of a patient the number of years of life
lost depends on age and was related to relevant life
expectancy tables14 and discounted at 3%.15 For the
primaryanalysis, a yearof life lostwas assignedacost of
$150, reflecting the WHO benchmark for an “attrac-
tive” intervention in terms of cost effectiveness.16 All
other costs and outcomes accrue instantaneously, with
Tree 1: Febrile patient
Test (Rapid diagnostic test or microscopy)
Antibiotic
Self limiting
Test negative Test positive
Presumptive treatment
Severe
No antibiotic
? Other
febrile illness
True positive
Appropriate
treatment
Appropriate
treatment
Appropriate
treatment
Tree 1: Febrile patient
False negative or untreated bacterial episode
Viral, self limiting Bacterial, appropriate treatment
Receive
antimalarial
Adhere
Dies Recovers
? Other
febrile illness
? Other
febrile illness
Malaria
Appropriate
treatment
Malaria True negative
False negative
No Yes Yes
Yes
Yes Yes
Dies Recovers
Yes
Yes
Viral, self limiting Bacterial, untreated
Untreated Treated
No
No
Yes
Yes Yes
Fig 1 Decision trees in the model. The probabilities for developing severe illness and case fatality rates differ with respect to age,
transmission intensity, and status as either false negative or untreated bacterial illness (see table 1)
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no further discounting required. The outcomes of the
different branches summarise the total costs of treating
1000 patients with each strategy. The benefits of
diagnosis are integrated in this value (as the averted
cost of life years lost), so the intervention with the
lowest total cost is the most attractive.
We tested the results for sensitivity to variation in all
measures and produced a tornado graph to identify the
measurewithhighest influence.The sensitivityanalysis
also presents results when the value for microscopy
sensitivity is set at 95%, WHO’s minimum require-
ment for amalaria diagnostic test. This was included as
the documented sensitivity for microscopy in the trial
was very low—under 75%.
RESULTS
Themodel output shows the importance of response to
test results to the cost-benefit of diagnostic tests for
malaria and indicates some situations where even
modest compromises in consistent response rate led to
higher expenditure than that incurred with presump-
tive treatment. This depends critically on transmission
rates and age of the patient.
In a low transmission setting (prevalence of malaria
10% in those with febrile illness) and for a 15 year old,
usingeither test incurredhigher costs thanpresumptive
treatment when consistent response rate was below
20%, and testing became increasingly attractive as
response consistency improved (fig 2). For instance, at
a consistent response rate of 50%, either test was less
costly than presumptive treatment (as both tests were
below the presumptive treatment threshold), about
$5200 (£2500; €3500) for 1000 patients. Above this
level of consistent response rate, rapid diagnostic tests
became marginally more attractive, but despite their
higher sensitivity they did not have a great advantage
over microscopy in low transmission settings.
In a high transmission setting (prevalence of 60%)
and for a 15 year old, both tests incurred higher costs
than a strategy of presumptive treatment if consistent
response rate was below approximately 65% (fig 2).
The graph shows that the two tests followed conflicting
trends as response improved further. Although con-
sistent response to results of rapid diagnostic tests led to
substantial cost savings, the cost of microscopy
continued to rise as consistent response rate improved,
mainly because of its low sensitivity, which resulted in
considerable numbers of false negative results.
Figure 3 compares each of the tests directly with
presumptive treatment across all levels of prevalence
and consistent response rate, showing the proportional
change in cost of rapid diagnostic tests andmicroscopy
relative to presumptive treatment. The upper left
corners in both charts indicate that in low prevalence
settings, use of either test with consistent response to
results led to cost savings of between 50% and 100% as
compared with presumptive treatment. As prevalence
increases to the medium-high range, however, con-
sistent response rate must increase more than propor-
tionately if use of the tests is to remain attractive. At
very high levels of prevalence, both tests appeared
more costly, irrespective of response by clinicians,
primarily because of imperfect test sensitivities, and
presumptive treatment remained the more efficient
option.
To illustrate these findings, the levels of consistent
response rate seen in the trial (about 50%) imply that
Table 2 | Transition probabilities and case fatality rates by age and transmission intensity
Age (years)
Under 5 5 to 10 ≥10
Probability untreated malaria becomes
severe*:
1% prevalence 0.075 0.050 0.011
10% 0.075 0.026 0.009
20% 0.075 0.011 0.006
30% 0.075 0.010 0.004
40% 0.075 0.010 0.003
50% 0.075 0.010 0.002
60% 0.075 0.010 0.002
70% 0.075 0.010 0.001
80% 0.075 0.010 0.001
90% 0.075 0.010 0.001
Case fatality rate, treated severe malaria 0.05 0.10 0.20
Case fatality rate, untreated severe malaria 0.30 0.40 0.50
Probability non-malarial febrile illness
becomes severe
0.01 0.005 0.010
Case fatality rate, non-malarial febrile illness 0.1 0.20 0.30
*Initial estimates based on previous analyses,13 27 then classified by transmission intensity based on expert
opinion.
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rapid diagnostic tests would increase costs by 250% in
low transmission settings and 35% in high transmission
settings in comparison to settings where no patients
withnegative test resultswereprescribed antimalarials.
Increases were similar for microscopy at low transmis-
sion, but in a moderate to high transmission setting the
cost increase was only 10%. At higher prevalence,
microscopy would become less attractive than pre-
sumptive treatment.
Figure 4 explores the most attractive strategy at all
prevalences and levels of consistent response rate,
using profiles for patients aged 3, 7, and 25 years. They
indicate that using either parasitological test for
younger patients was unattractivein settings of high
transmission, even if response to tests was fully
consistent.
Sensitivity analysis
Results were most sensitive to the cost assigned to a
year of life lost. Higher values for this variable led to
scenarios that were more costly and effective being
considered more attractive. If the cost of years of life
lost is ignored, rapiddiagnostic testswouldneverbe the
most efficient option, while microscopy was still
attractive although decreasingly so as prevalence
increased and response fell.
Figure 5 shows the circumstances under which each
of the strategies is most attractive, stratified by cost per
year of life lost averted. At a value of $25 (the value
where WHO considers interventions to be “very
attractive”), rapid diagnostic tests gained some advan-
tage in themid-range of prevalence as long as response
was consistent with results, and microscopy remained
the preferred option for low prevalence areas even at
low levels of consistent response rate. Using $150 per
year of life lost, rapid diagnostic tests became the
preferredoptionup toaprevalenceof about70%,when
presumptive treatment became the more efficient
option. At a value of $680—twice the Tanzanian
gross national incomeper capita for the year 2005,17 an
alternative rule of thumb18—rapid diagnostic tests
dominated across all but the lowest levels of consistent
response rate and highest levels of prevalence.
Lastly, we ran the model using a value for micro-
scopy sensitivity (95%)higher than that seen in the trial.
At this level, microscopy was the preferred option for
most levels of consistent response rate and when
prevalence was up to 90% (fig 6).
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DISCUSSION
A major barrier to the use of artemisinin combination
therapy is considered to be its cost. Targeting drugs to
people in greatest need is essential if programmesare to
be sustainable. Diagnostic tests are costly and have to
be cost beneficial if they are to be used. This study
shows that clinicians’ response to test results has a
major impact on the total cost of both microscopy and
rapid diagnostic tests, and that this varies with rate of
transmission of malaria. In low transmission settings,
testing remains attractive even when consistent
response rate is relatively poor, while at higher
prevalences consistent response rate must increase
more than proportionately for tests to remain attrac-
tive. At very high prevalences, presumptive treatment
remains attractive given the imperfect sensitivity of
tests (particularly microscopy) under field conditions.
The relatively low accuracy of microscopy under field
conditions explains its poor performance relative to
rapid diagnostic tests.
Previous economic analyses of malaria diagnostic
tests for febrile patients have ranged from those based
on simple formulas (comparing the cost of treatment to
the cost of the test plus the cost of treatment across
differing levels of prevalence) to more advanced
analyses seeking to incorporate test accuracy and the
cost of false results.8-22 A recent study evaluating the
effectiveness of introducing new diagnostic tests for
malaria included several novel elements, such as the
infrastructure required for the tests and subsequent
accessibility, and an estimate of “harm of treatment”
associated with antimalarials.8 The cost implications of
inconsistent response to test results have, however,
largely been ignored, despite the overwhelming
evidence that this is a problem throughout Africa.
This study shows the importance of allowing for
compromised consistency in response to test results,
both in terms of implications for expenditure on
diagnostic tests and treatment and for potential health
outcomes. These implications are likely to hold for
economic assessments of diagnostic tests other than
those for malaria.
Limitations
The study assumed that only febrile patients were
tested, although in reality almost 20% of antimalarials
prescribed were given to patients who did not have a
history of fever, of whomonly 1.7%were parasitaemic.
This runs counter to guidelines such as those of WHO
and theTanzanianMinistry ofHealth andwill increase
the waste of resources.23 24 In addition, the study
evaluated the impact of testing on prescribing anti-
malarials only, although testsmay influence clinicians’
behaviour in prescribing additional drugs, especially
antibiotics.
Three further potential limitations of the methods
should be highlighted. Some of the data within the
model had to be estimated from indirect sources
because locally relevant data are not available. These
points are highlighted as “expert opinion” in the tables.
Secondly, the model does not differentiate between
patients with mild symptoms but varying levels of
parasitaemia, largely because the evidence that level of
parasitaemiainfluences outcome ismixed. Thirdly, the
methods of estimating rate of transmission from
hospital data are inevitably not precise. Characterising
transmission is prone to numerous difficulties. In this
study we used prevalence of parasitaemia among
febrile patients, although this method is subject to
several limitations. An alternative method would be
the use of serological markers as evidence of longer
termexposure,25 although the impact of thismethodon
results obtained in our model would be small. Data for
case fatality rates for untreated malaria, for instance,
cannot be measured precisely, and the interaction
between case fatality ratesand rates of transmission and
age adds an additional level of uncertainty. Future
models couldallowusers to enter theirownestimates to
observe the impact of their variation on final results.
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Policy implications
This study has confirmed findings that show the
potential cost savings from use of a diagnostic test
before prescribing antimalarial treatment, if test results
areused toguide theprescribingof antimalarials. It also
shows, however, that in some circumstances diagnostic
tests rapidly become less attractive when prescribers
even only partially ignore negative results. The
primary implication is therefore that response to test
results must be taken into account in designing public
health programmes, as investing in rapid diagnostic
tests without changing prescribing behaviour is unli-
kely to be cost beneficial.
Currently there are only preliminary data as to how
this behaviour change can be achieved, and change is
unlikely to be easy. Both the current levels of response
to treatment guidelines and the methods to improve
these are under-researched.26 Influencing prescribers’
behaviourmight require changing thewhole approach
to treating febrile illnesses, and the reasons for current
(irrational) practice need to be understood. If pre-
scribers’ behaviour is driven by a perception that
patients expect to be treated for malaria, then either
patients’ expectations or prescribers’ perceptions will
need to be changed. Unfortunately there is little
evidence on howbest to do this inAfrica; the relevance
of lessons learnt in developed countries (for example,
reducing overprescription of antibiotics) is uncertain.
Effectivemethods to supportbehaviour changeneed to
be identified andpursued to ensure that the use of rapid
diagnostic tests and artemisinin combination therapies
is cost beneficial.
Investment in improving the quality of field micro-
scopy is also a priority. In this analysis, because of the
low levels of sensitivity of microscopy seen in practice,
its use currently results in high total costs in most
circumstances, andwith high prevalence ofmalaria the
total costs increased further as response to test results
improved. Where microscopy is used for routine
diagnosis, measures to ensure higher accuracy as well
as response consistent with test results are necessary to
maximise cost effectiveness. Changing prescribers’
behaviourwill have costs, but these can be offset by the
savings gained with better response to test results.
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